Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

100%(5 trials)

Phase Distribution

Ph phase_1

20%

Ph phase_2

60%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

3(60.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (20.0%)

Phase 23 (60.0%)

Phase 31 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_3

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

NCT01770743

completedphase_2

BARDA Securing Anthrax Immunity For the Elderly

NCT03518125

Clinical Trials (5)

Showing 5 of 5 trials

NCT03877926Phase 3

VELOCITY: An Anthrax Vaccine Clinical Study

Completed

NCT04067011Phase 2

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

Completed

NCT04660201Phase 1

Anthrax AV7909 Liquid vs Lyophilized

Completed

NCT01770743Phase 2

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

Completed

NCT03518125Phase 2

BARDA Securing Anthrax Immunity For the Elderly

Completed

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5